Abstract:Background: Genetic risk factors impact around 15% of Parkinson's disease (PD) patients and at least 23 variants have been identified including Glucocerebrosidase (GBA) gene variants. Using different clinical and instrumental qualitative-based data, various studies have been published on GBA-PD cohorts which suggested possible differences in dopaminergic nigrostriatal denervation pattern, particularly in caudate and putamen nuclei. Methods: This retrospective study included two consecutive homogenous cohorts of GBA-PD and idiopathic (I-PD) patients. Each consecutive GBA-PD patient has been matched with a 1:1 pairing method with a consecutive I-PD subject according to age, age at disease onset, sex, Hoehn & Yahr (H&Y) staging scale and comorbidity level (CCI). Semiquantitative volumetric data by the DaTQUANTTM software integrated in the DaTSCAN exam performed at time of the diagnosis (SPECT imaging performed according to current guidelines of I-123 FPCIT SPECT imaging) were extrapolated. Bilateral specific binding ratios (SBR) at putamen and caudate levels were calculated, using the occipital lobes uptake. The Mann-Whitney test was performed to compare the two cohorts while the Spearman's test was used to find correlations between motor and volumetric data in each group. Bonferroni correction was used to account for multiple comparisons. Results: Two cohorts of 25 patients each (GBA-PD and I-PD), were included. By comparing GBA-PD and I-PD patients, lower SBR values were found in the most affected anterior putamen and left caudate of the GBA-PD cohort. Furthermore, in the GBA-PD cohort the SBR of the most affected posterior putamen negatively correlated with the H&Y scale. However, none of these differences or correlations remained significant after Bonferroni correction for multiple comparisons. Conclusions: We observed differences in SBR values in GBA-PD patients compared with I-PD. However, these differences were no longer significant after Bonferroni multiple comparisons correction highlighting the need for larger, longitudinal studies.

Expanding the Spectrum of GBA1-Associated Neurodegenerative Diseases in an Italian Family

[Genetic and Clinical Analysis in a Parkinson's Disease Family Caused by Expansion of SCA2].

Severe GBA1 variants drive the GBA-PD clinical phenotype: implications for counselling and clinical trials

Putative second hit rare genetic variants in families with seemingly GBA-associated Parkinson's disease

Functional Study of SNCA p.V15A Variant: Further Linking α‐Synuclein and Glucocerebrosidase

Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease

A Novel Homozygous SYNJ1 Mutation in Two Siblings with Typical Parkinson's Disease.

Quantitative dopamine transporter imaging assessment in Parkinson's disease patients carrying GBA gene mutations compared with idiopathic PD patients: A case-control study

A Global Perspective of GBA1-Related Parkinson's Disease: A Narrative Review

The loss of function GBA1 c.231C > G mutation associated with Parkinson disease

GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice

Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers

GBA1-Associated Parkinson's Disease Is a Distinct Entity

Genetic mutations in Parkinson’s disease: screening of a selected population from North-Eastern Italy

Genetic, transcriptomic, histological, and biochemical analysis of progressive supranuclear palsy implicates glial activation and novel risk genes

Variability of the clinical phenotype in an Italian family with dementia associated with an intronic deletion in the GRN gene

Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutation

Intrafamilial variable phenotype including corticobasal syndrome in a family with p.P301L mutation in the MAPT gene: first report in South America

African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1

The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson's Disease: a New Genetic State of the Art

Cognitive phenotyping of GBA1-Parkinson's disease: A study on deep brain stimulation outcomes